An interventional study of Pituitary adenylate cyclase activating polypeptide-38 and Placebo in Post-Traumatic Headache, sponsored by Danish Headache Center. Status unknown at 1 site in Denmark. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-06-22.
Sponsored by Danish Headache Center · Not applicable, Interventional, and Basic science
The aim is to investigate whether signaling molecule PACAP-38 induces headache with migraine-like features in people with persistent post-traumatic headache (PTH) attributed to mild traumatic brain injury (mTBI).
188 studies on the registry are indexed under Post-Traumatic Headache; 50 are open to participants now.
This study's planned enrollment of 21 is below the median of 44 across 166 interventional studies indexed under Post-Traumatic Headache.
Browse Post-Traumatic Headache studies →Danish Headache Center is the lead sponsor of 125 studies on the registry; 15 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
A time- and volume-controlled infusion pump is used to administer PACAP-38 by intravenous infusion over 20 minutes.
Drug: Pituitary adenylate cyclase activating polypeptide-38
A time- and volume-controlled infusion pump is used to administer placebo (isotonic saline) by intravenous infusion over 20 minutes.
Drug: Placebo
Study participants will be allocated to receive continuous intravenous infusion of 10 pmol/kg/min PACAP-38.
Also known as: PACAP-38
Study participants will be allocated to receive continuous intravenous infusion of 20 mL placebo (isotonic saline).
Also known as: Isotonic Saline
Incidence of Migraine-Like Headache
Difference in incidence of headache with migraine-like features (0 to 12 hours) between PACAP-38 and placebo.
Time frame: 12 Hours
Headache Intensity Scores
Difference in area under the curve (AUC) for headache intensity scores (0 to 12 hours) between PACAP-38 and placebo.
Time frame: 12 Hours
This study is status unknown, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Danish Headache Center